Respiratory Infections

Implications for antimicrobial use and antimicrobial resistance.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.

Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

New systematic review data suggest most patients who test positive without symptoms will remain asymptomatic over time.

A France-based assessment of the IL-1 inhibitor was ended early on the recommendation of the safety monitoring board early this year.

Avian flu outbreaks have been detected in countries all over the world, but influenza activity in humans remains uncharacteristically low for this point in the season.

An online survey-based assessment showed older adults and minorities have been more likely to wear masks in public.

The agency set a PDUFA date for July 18 for Merck's V114 vaccine.

Ability for rapid diagnosis to treat and prevent communicable diseases is a public health issue that goes beyond the current pandemic.

The discovery of unique virus traits may explain why some patients have more severe responses to the disease.

The ability to monitor, mitigate, and prevent new variant spread could influence the odds of majority immunity.

More transmissible variants are emerging quickly. An expert explains why it's expected, but concerning.

A discussion around the relatively shocking effect of the virus on infants, and what's needed in long-term assessment of the patient group.

From vaccine studies to reopening institutions, pooled testing may be a hugely beneficial tool.

The global health agency provided current insights and advisories into 4 different variants observed during COVID-19 this year.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

A new multicenter study confirms earlier findings that the panel performs well against the more time-intensive quantitative bacterial culture.

Though regulatory authorization has not been granted, the company intends to vaccinate up to 50 million people prior to the Lunar New Year.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

While the number of study participants was too small to extrapolate for the whole population, the authors said they were encouraged.

Influenza and pneumonia, though rare, occurred at roughly the same rate in both the high-dose and standard-dose vaccine groups.

A universal flu vaccine is also another step closer, according to researchers at Mount Sinai.

The updated vaccine efficacy and safety outcomes include 37,000-plus participants from the ongoing, multi-national trial.

Investigators identify gene expression which may explain the highly transmissible nature of the virus.